ArticleTheranostics2024
DNASE1L3-mediated PANoptosis enhances the efficacy of combination therapy for advanced hepatocellular carcinoma.
Article in Theranostics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Novel diagnostic and therapeutic strategies based on PANoptosis for hepatocellular carcinoma.Cancer biology & medicine · 2025Pooled it
- Reprogramming of cell death in gastric cancer: From molecular mechanisms to therapeutic potential (Review).International journal of molecular medicine · 2026Review
- Current status and challenges of immune checkpoint inhibitors in liver cancer: from monotherapy to combination strategies.Medical oncology (Northwood, London, England) · 2026Review
- Immune response to DNA and RNA: structural insights, molecular mechanisms, and therapeutic targeting.Molecular biomedicine · 2026Review
- PANoptosis and Immune Remodeling in the Tumor Microenvironment.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026Review
- PANoptosis in the pathogenesis of myelodysplastic syndromes.Molecular oncology · 2026Review
- Comprehensive analysis to develop a stromal senescence-associated gene signature for predicting hepatocellular carcinoma.Translational cancer research · 2026Article
- Exploring Transcriptomic and MRI-Derived Parameters Correlations in NAFLD Fibrosis: Insights from a Rat Model.Digestive diseases and sciences · 2026Article
- NDUFA4L2 regulates the progression and chemotherapy sensitivity of HNSCC by inhibiting PANoptosis.NPJ precision oncology · 2026Article
- Extrachromosomal DNA drives molecular and clinical heterogeneity in hepatocellular carcinoma: a multi-omics analysis and prognostic model development.Human genomics · 2026Article
- Identification and validation of NETs-related biomarkers in hepatocellular carcinoma through bioinformatics analysis and machine learning algorithms.Discover oncology · 2026Article
- Research progress of tertiary lymphoid structure in hepatocellular carcinoma: from prognostic biomarkers to new strategies for immunotherapy.Frontiers in immunology · 2026Review
- Transferrin receptor serves a role in promoting PANoptosis in thyroid cancer.Oncology letters · 2026Article
- Article
- A Comprehensive Review of AIM2 in Cancer: Functional Roles, Molecular Pathways, and Clinical Relevance.Journal of immunology research · 2026Review
- PANoptosis: potential new targets and therapeutic prospects in digestive diseases.Apoptosis : an international journal on programmed cell death · 2025Review
- PANoptosis in hepatocellular carcinoma: Underlying mechanisms.World journal of hepatology · 2025Review
- Therapeutic targeting of cell death-immune crosstalk in cancer to rewire the tumor immune microenvironment.Molecular cancer · 2025Review
- Comprehensive bioinformatic analysis reveals sorafenib response-related prognostic signature in hepatocellular carcinoma.Journal of gastrointestinal oncology · 2025Article
- Machine learning model in multi-omics perspective demystifies the prognostic significance of crotonylation heterogeneity in clear cell renal cell carcinoma.BMC urology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.